With regulatory support from the EMA and financial backing from the European Investment Bank (EIB), Biondvax Pharmaceuticals Ltd. moved a step closer to initiating the pivotal phase III trial of its universal flu vaccine candidate, Multimeric-001 (M-001), by putting a master service agreement in place with a contract research organization (CRO) for the trial, expected to begin in the third quarter prior to the 2018-19 Northern Hemisphere flu season.